Trial Profile
Circulating tumour-derived DNA as a predictive biomarker to evaluate response to nivolumab treatment in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Nov 2017 New trial record
- 24 Oct 2017 Results published in the European Journal of Cancer